Life sciences companies need to take further steps to protect themselves against the growing problem of counterfeit drugs
When talking about counterfeiting, most of us think about major consumer brands but, unfortunately, counterfeiting is also a major and growing problem within the life sciences industry – and to make matters worse, nobody knows exactly how big the problem is.
Lonza and NNIT partner to speed up MES projects
Across the life sciences industry, pharma companies are seeking new ways to respond to the high agility required to produce complex products like personalized cancer treatment, cell and gene therapy and Covid-19 vaccines. Central to these efforts is the manufacturing execution system (MES), which allows pharma companies to adopt pharma 4.0 production and manage their data flows to expedite product